de Man R A, Sprey R P, Niesters H G, Heijtink R A, Zondervan P E, Hop W, Schalm S W
Department of Internal Medicine II, Erasmus University, Rotterdam, The Netherlands.
J Hepatol. 1995 Dec;23(6):662-7. doi: 10.1016/0168-8278(95)80031-x.
BACKGROUND/AIMS: Our aim was to evaluate the clinical outcome and survival of patients with anti-Delta positive liver disease in The Netherlands.
We evaluated those patients visiting our hospital between 1978 and 1993 with respect to clinical, virological and histological parameters. During the follow-up period the occurrence of complications of the liver disease and survival was determined. Thirty patients with a median age of 34 years (range 21-52) were included.
During an average follow up of 4.8 years, nine patients died. The overall 5-year survival as estimated by Kaplan-Meyer analysis was 71%, which was comparable to hepatitis B cirrhosis patients. However, in the group without active hepatitis B replication (HBeAg-negative) a clear trend towards a worse survival was identified in Delta cirrhosis patients. Complications and deaths occurred exclusively in the patient group with cirrhotic liver disease. The complications (ascites, elevated bilirubin >34 micro mol/l), variceal bleeding and spontaneous bacterial peritonitis) occurred in 52% of the patients with a follow up of more than 6 months (n=27). Fifty-seven percent of those patients died. In our population anti-Delta positive liver disease affects predominantly young patients and is related to advanced liver disease.
In view of the high death rate, liver transplantation should be considered when signs or symptoms of decompensated liver disease occur.
背景/目的:我们的目的是评估荷兰抗δ阳性肝病患者的临床结局和生存率。
我们评估了1978年至1993年间来我院就诊的患者的临床、病毒学和组织学参数。在随访期间,确定肝病并发症的发生情况和生存率。纳入了30例患者,中位年龄为34岁(范围21 - 52岁)。
在平均4.8年的随访期间,9例患者死亡。通过Kaplan - Meyer分析估计的总体5年生存率为71%,与乙肝肝硬化患者相当。然而,在无乙肝病毒活跃复制(HBeAg阴性)的组中,δ肝硬化患者的生存率有明显变差的趋势。并发症和死亡仅发生在肝硬化肝病患者组中。随访超过6个月的患者(n = 27)中有52%发生了并发症(腹水、胆红素升高>34微摩尔/升)、静脉曲张出血和自发性细菌性腹膜炎)。这些患者中有57%死亡。在我们的研究人群中,抗δ阳性肝病主要影响年轻患者,且与晚期肝病有关。
鉴于高死亡率,当出现失代偿性肝病的体征或症状时,应考虑肝移植。